Amgen Worldwide
A biotechnology pioneer since 1980, Amgen has reached millions of patients around the world.
オンラインリソース
アムジェンは、患者さんが関心のある分野について学べるよう、多数のリソースを用意しております。
疾患教育
重点領域
A biotechnology pioneer since 1980, Amgen has reached millions of patients around the world.
アムジェンは、患者さんが関心のある分野について学べるよう、多数のリソースを用意しております。
この資料は、米国アムジェン社が2021年4月16日に発表したニュースリリースの日本語抄訳であり、報道関係者各位の利便性のために提供するものです。この資料の正式言語は英語であり、その内容及びその解釈については英語を優先します。詳細はhttps://www.amgen.com/newsroomをご参照下さい。
カリフォルニア州サウザンドオークス（2021年4月16日）– アムジェン社（ナスダック：AMGN）は本日、免疫・腫瘍およびがん標的治療の開発に注力する臨床ステージのバイオテクノロジー企業であるFive Prime Therapeutics社（ナスダック：FPRX）の普通株式のすべての発行済み株式を一株あたり38.00ドルの現金で取得すると発表した、株式公開買い付けを完了したことを発表しました。株式公開買付けおよびその後の合併を完了するためにアムジェンが支払う総額は約19億ドルであり、関連する取引費用には影響しません。
アムジェンの会長 兼 最高経営責任者のRobert A. Bradwayは次のように述べています。「Five Prime Therapeutics社のポートフォリオはアムジェン社の主要なオンコロジー・ポートフォリオに合致しており、世界のがん死亡原因の第3位である胃がんに対するファースト・イン・クラスのプログラムである第Ⅲ相試験が予定されているbemarituzumabを有しています。Five Prime Therapeutics社からアムジェン社に加わる専任の専門家たちと共に、bemarituzumabを速やかに第Ⅲ相試験に移行させ、胃がん患者さんにお届けするためのステップを一歩前に進める予定です」
アムジェン社が有するまたは補完的な、転移性胃がん・胃食道接合部（GEJ）がんに対する開発能力と、生物学的製剤の製造ノウハウおよび世界的な販売実績により、日本、韓国、ラテンアメリカなどの胃がんの有病率が高い地域でbemarituzumabを患者さんにお届けすることができます。アムジェン社は引き続き、アムジェン社のパイプラインに加わるFive Prime Therapeutics社のオンコロジー・アセットのレビューを行います。
本株式公開買付けの預託機関によると、本株式公開買付けの終了時点で約40,392,569株が有効に応募され、本株式公開買付けの中で適切に撤回されなかったため、その数はFive Prime Therapeutics社の発行済株式の約87.8%に相当しました。Five Prime Therapeutics社の発行済株式の50％を少なくとも1株でも超える数の株式が有効に応募され、本株式公開買付けの終了前に適切に撤回されないという、本株式公開買付けの条件が満たされました。その結果、アムジェン社は、そのように有効に応募されたすべての株式に対する支払いを受諾し、そのように有効に応募されたすべての株式に対する支払いを迅速に（いずれにしても2営業日以内に）行います。
本株式公開買付けの完了後、アムジェン社の完全子会社であるFranklin Acquisition Sub, Inc.社はFive Prime Therapeutics社と合併し、合併後の存続会社はFive Prime Therapeutics社となります。本日行われた合併の結果、残りの適格なFive Prime Therapeutics社の株式はすべて、本株式公開買付けで支払われたのと同じ価格（適格な株式とは、デラウェア法に基づく適正な株式買取請求権の適正な行使を完了した株主が保有している株式と、アムジェン社、アムジェン社の完全子会社またはFive Prime Therapeutics社が保有している株式を除く）である、一株あたり38.00ドルの現金から適用される源泉徴収税と利子を差し引いた金額を受領する権利に転換されました。本合併の完了後、Five Prime Therapeutics社の株式はナスダック・グローバル・セレクト・マーケットでの取引を停止しています。
アムジェン社について
アムジェン社は、重篤な疾患に苦しむ患者さんのために、生物学的に革新的な治療を探索・開発・製造・提供する可能性を切り拓いていきます。このアプローチは、疾患の複雑性の解明と人体の生物学上の基本を理解するために、先進的なヒト遺伝学などの手法を活用することから始まります。
アムジェン社は、アンメット・メディカル・ニーズが大きい領域に焦点を絞り、生物製剤の製造に関する専門知識を活用して医療効果の向上と人々の生活に画期的な改善をもたらすソリューションを追求しています。1980年に創業したバイオテクノロジーのパイオニアであるアムジェン社は、世界最大の独立バイオテクノロジー企業に成長し、世界中の多くの患者さんに貢献しており、革新的な可能性が期待されるパイプラインを開発しています。
詳細については www.amgen.comをご覧になるか、www.twitter.com/amgenをフォローしてください。
Amgen Forward-Looking Statements
This news release contains forward-looking statements that are based on the current expectations and beliefs of
Amgen. All statements, other than statements of historical fact, are statements that could be deemed
forward-looking statements, including any statements on the outcome, benefits and synergies of the Five Prime
Therapeutics, Inc. acquisition, as well as estimates of revenues, operating margins, capital expenditures, cash,
other financial metrics, expected legal, arbitration, political, regulatory or clinical results or practices,
customer and prescriber patterns or practices, reimbursement activities and outcomes, effects of pandemics or
other widespread health problems such as the ongoing COVID-19 pandemic on our business. Forward-looking
statements involve significant risks and uncertainties, including those discussed below and more fully described
in the Securities and Exchange Commission reports filed by Amgen, including our most recent annual report on
Form 10-K and any subsequent periodic reports on Form 10-Q and current reports on Form 8-K. Unless otherwise
noted, Amgen is providing this information as of the date of this news release and does not undertake any
obligation to update any forward-looking statements contained in this document as a result of new information,
future events or otherwise.
No forward-looking statement can be guaranteed and actual results may differ materially from those we project. Discovery or identification of new product candidates or development of new indications for existing products cannot be guaranteed and movement from concept to product is uncertain; consequently, there can be no guarantee that any particular product candidate or development of a new indication for an existing product will be successful and become a commercial product. Further, preclinical results do not guarantee safe and effective performance of product candidates in humans. The complexity of the human body cannot be perfectly, or sometimes, even adequately modeled by computer or cell culture systems or animal models. The length of time that it takes for us to complete clinical trials and obtain regulatory approval for product marketing has in the past varied and we expect similar variability in the future. Even when clinical trials are successful, regulatory authorities may question the sufficiency for approval of the trial endpoints we have selected. We develop product candidates internally and through licensing collaborations, partnerships and joint ventures. Product candidates that are derived from relationships may be subject to disputes between the parties or may prove to be not as effective or as safe as we may have believed at the time of entering into such relationship. Also, we or others could identify safety, side effects or manufacturing problems with our products, including our devices, after they are on the market. There can be no guarantee that we will be able to realize any of the potential strategic benefits, synergies or opportunities as a result of the Five Prime acquisition. Nor can there be any guarantee that bemarituzumab will be submitted or approved for sale in any market, or at any particular time. Neither can there be any guarantee that such product will be successfully commercialized even if regulatory approvals are obtained. In particular, our expectations could be affected by, among other things: potential regulatory actions or delays with respect to the development of bemarituzumab; the potential that the strategic benefits, synergies or opportunities expected from the acquisition may not be realized or may take longer to realize than expected; and the successful integration of Five Prime into Amgen subsequent to the closing of the transaction and the timing of such integration.
Our results may be affected by our ability to successfully market both new and existing products domestically and internationally, clinical and regulatory developments involving current and future products, sales growth of recently launched products, competition from other products including biosimilars, difficulties or delays in manufacturing our products and global economic conditions. In addition, sales of our products are affected by pricing pressure, political and public scrutiny and reimbursement policies imposed by third-party payers, including governments, private insurance plans and managed care providers and may be affected by regulatory, clinical and guideline developments and domestic and international trends toward managed care and healthcare cost containment. Furthermore, our research, testing, pricing, marketing and other operations are subject to extensive regulation by domestic and foreign government regulatory authorities. Our business may be impacted by government investigations, litigation and product liability claims. In addition, our business may be impacted by the adoption of new tax legislation or exposure to additional tax liabilities. If we fail to meet the compliance obligations in the corporate integrity agreement between us and the U.S. government, we could become subject to significant sanctions. Further, while we routinely obtain patents for our products and technology, the protection offered by our patents and patent applications may be challenged, invalidated or circumvented by our competitors, or we may fail to prevail in present and future intellectual property litigation. We perform a substantial amount of our commercial manufacturing activities at a few key facilities, including in Puerto Rico, and also depend on third parties for a portion of our manufacturing activities, and limits on supply may constrain sales of certain of our current products and product candidate development. An outbreak of disease or similar public health threat, such as COVID-19, and the public and governmental effort to mitigate against the spread of such disease, could have a significant adverse effect on the supply of materials for our manufacturing activities, the distribution of our products, the commercialization of our product candidates, and our clinical trial operations, and any such events may have a material adverse effect on our product development, product sales, business and results of operations. We rely on collaborations with third parties for the development of some of our product candidates and for the commercialization and sales of some of our commercial products. In addition, we compete with other companies with respect to many of our marketed products as well as for the discovery and development of new products. Further, some raw materials, medical devices and component parts for our products are supplied by sole third-party suppliers. Certain of our distributors, customers and payers have substantial purchasing leverage in their dealings with us. The discovery of significant problems with a product similar to one of our products that implicate an entire class of products could have a material adverse effect on sales of the affected products and on our business and results of operations. Our efforts to collaborate with or acquire other companies, products or technology, and to integrate the operations of companies or to support the products or technology we have acquired, may not be successful. A breakdown, cyberattack or information security breach could compromise the confidentiality, integrity and availability of our systems and our data. Our stock price is volatile and may be affected by a number of events. Global economic conditions may magnify certain risks that affect our business. Our business performance could affect or limit the ability of our Board of Directors to declare a dividend or our ability to pay a dividend or repurchase our common stock. We may not be able to access the capital and credit markets on terms that are favorable to us, or at all.
###
この件に関するお問い合わせ先
アムジェン株式会社（東京）
コーポレート・アフェアーズ
TEL 03-4590-1771
アムジェン社（カリフォルニア州サウザンドオークス）
Megan Fox, 805-447-1423（メディア向け）
Arvind Sood, 805-447-1060（投資家向け）